Gastroenterology Research and Practice / 2022 / Article / Tab 5 / Research Article
The Influence of Radiological “Disappearing Lesions” on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy Table 5 Univariate and multivariate analysis of progression-free survival.
Risk factors Univariate analysis Multivariate analysis HR (95% CI) valueHR (95% CI) valueAge (>/≤52, years) 4.532 (1.785-11.503) 0.001 3.690 (1.173-11.607) 0.026 Sex (male/female) 5.016 (1.753-14.349) 0.003 1.570 (0.430-5.736) 0.495 Size of liver metastasis (>/≤5 mm) 2.715 (0.806-9.143) 0.107 Primary site (colon/rectum) 1.476 (0.628-3.469) 0.372 Extrahepatic metastasis (yes/no) 1.002 (0.433-2.318) 0.996 T staging of the primary tumor 0.398 (0.103-1.536) 1.181 Lymph node metastasis (yes/no) 7.706 (0.936-63.390) 0.058 BMI (>/≤23.4) 0.646 (0.270-1.544) 0.326 CEA (>/≤5) 2.140 (0.889-5.152) 0.090 CA19-9(>/≤40) 0.930 (0.377-2.294) 0.875 Liver metastasis (simultaneous/metachronous) 1.441 (0.486-4.266) 0.510 Treatment regimens (chemotherapy alone/targeted therapy alone/chemotherapy combined with targeted therapy group) 2.593 (1.310-5.134) 0.006 2.703 (1.081-6.758) 0.033 Segment of liver metastases 0.928 (0.744-1.157) 0.506
Note:
value <0.05. Abbreviations: PFS: progression-free survival; CI: confidence interval; BMI: body mass index; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 199.